# EDGAR Filing Document

**Accession Number:** 0001042074
**File Stem:** 0001193125-23-013148
**Filing Date:** 2023-1
**Character Count:** 4597
**Document Hash:** 415c0ce7c1658bada7fc78ba9a4a00b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-013148.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001193125-23-013148

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230123

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CymaBay Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042074
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 943103561
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36500
- **FILM NUMBER:** 23544518

**BUSINESS ADDRESS:**
- **STREET 1:** 7575 GATEWAY BOULEVARD
- **STREET 2:** SUITE 110
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560
- **BUSINESS PHONE:** 510-293-8800

**MAIL ADDRESS:**
- **STREET 1:** 7575 GATEWAY BOULEVARD
- **STREET 2:** SUITE 110
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METABOLEX, INC.
- **DATE OF NAME CHANGE:** 20090721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METABOLEX INC
- **DATE OF NAME CHANGE:** 19970710

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, DC 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### Date of Report (Date of earliest event reported): January 23, 2023

------

## CymaBay Therapeutics, Inc.

#### (Exact name of Registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36500** | **94-3103561** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### 7575 Gateway Blvd., Suite 110

#### Newark, CA 94560

#### (Address of principal executive offices)
(510) 293-8800

#### (Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>symbol(s)** | **Name of each exchange<br>on which registered** |
| Common stock, $0.0001 par value per share | CBAY | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01 Other Events.
On January 23, 2023, CymaBay Therapeutics, Inc. suspended the use of its prospectus filed with the Securities and Exchange Commission (the "SEC") and dated July 13, 2020 relating to the Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated July 2, 2020 (the "Sales Agreement"), by and between CymaBay and Cantor Fitzgerald & Co. CymaBay will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC. Other than the termination of the prospectus relating to the Sales Agreement, the Sales Agreement remains in full force and effect.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| CymaBay Therapeutics, Inc. | CymaBay Therapeutics, Inc. |
| By: | /s/ Paul Quinlan |
| Name: | Paul Quinlan |
| Title: | General Counsel |

---

Dated: January 23, 2023